Search Results 181-190 of 11368 for ���������������������������:za33���24������ ������������������������ ������

  1. Radiology - Doctors - Mayo Clinic

    Learn about the radiology expertise and services offered at Mayo Clinic to solve the most serious and complex medical questions for people who turn to the ...

  2. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  3. Publications - Razvan M. Chirila, M.D. - Mayo Clinic

    2019 Oct; 34 (10):2288-2289 Epub 2019 July 24. View PubMed; Failing JJ, Dudek OA, Marin Acevedo JA, Chirila RM, Dong H, Markovic SN, Dronca RS. Biomarkers of ...

  4. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Study ACT16970 consists of 2 parts (A and B) as follows: Part A is a 24 week, double blind, placebo controlled part, preceded by a screening period of up to ...

  5. Clinical trials - Oncology (Medical)

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...

  6. https://www.mayoclinic.org/spanish_procedure_concepts.xml

  7. Tricuspid valve repair and tricuspid valve replacement - Doctors & Departments - Mayo Clinic

    These heart surgeries treat tricuspid valve regurgitation and stenosis and Ebstein anomaly, a type of congenital heart defect. Learn how they're done.

  8. Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma - Mayo Clinic

    Rochester, Minnesota: 24-011608; Scottsdale/Phoenix, Arizona: 24-011608. NCT ID: NCT06608927. Sponsor Protocol Number: PRISM-1. About this study. The purpose ...

  9. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  10. Oncology (Medical) - Clinical trials - Mayo Clinic

    The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in ...